OmniAb Results Presentation Deck
Performance Indicators
ACTIVE CLINICAL PROGRAMS AND APPROVED PRODUCTS
●
Our platform continues to generate new clinical programs
Three new programs entered the clinic in 2022, each with new modality, further
demonstrating the flexibility of our platform
●
M9140 (Merck KGaA): Antibody-drug conjugate anti-CEACAM5 in advanced solid
tumors
GEN1053 (Genmab/BioNTech): Hexabody anti-CD27 in malignant solid tumors
JNJ-79635322 (Janssen): Trispecific antibody in multiple myeloma
• Two programs exited the clinic in 2022, as two undisclosed partners realigned the
therapeutic area focus of their development pipelines
- Overall clinical attrition rate remains very low
Based on dialog with partners, we see potential for approximately 3-5 new entries
into clinical development for novel OmniAb-derived antibodies in 2023, with
programs addressing major unmet medical needs
30
25
20
15
10
5
0
Number of Active
Clinical Programs and
Approved Products
2016
2017
2018
2019
2020
2021
2022
6
OmniAbView entire presentation